| Not Yet Recruiting | This is a Clinical Study to Assess Whether the Combination of SJ733 and Tafenoquine Will be a Safe and Rapidly NCT07430592 | R. Kiplin Guy | Phase 2 |
| Not Yet Recruiting | Clinical Trial to Evaluate the Safety and Immunogenicity of the Vivaxin Vaccine for Malaria Caused by Plasmodi NCT07172724 | Federal University of Minas Gerais | Phase 1 |
| Recruiting | Serological Testing and Treatment for Plasmodium Vivax Malaria: a Trial in Ethiopia and Madagascar NCT06923592 | London School of Hygiene and Tropical Medicine | Phase 3 |
| Completed | Vivax Elimination With Tafenoquine (VET) Study NCT06575647 | Shoklo Malaria Research Unit | Phase 4 |
| Recruiting | An Interventional Study to Compare the Efficacy and Safety of Tafenoquine (TQ) and Primaquine (PQ) When Either NCT06666491 | GlaxoSmithKline | Phase 3 |
| Completed | Radical Cure (RC) With Tafenoquine or Primaquine After Semi-quantitative G6PD Testing: A Feasibility Study in NCT05361486 | Medicines for Malaria Venture | — |
| Recruiting | ACT vs CQ With Tafenoquine for P. Vivax Mono-infection NCT05788094 | Shoklo Malaria Research Unit | Phase 4 |
| Withdrawn | Primaquine Double Dose for Radical Cure of Plasmodium Vivax in Colombia NCT05232227 | University of California, San Francisco | Phase 2 / Phase 3 |
| Completed | Radical CUREfor MAlaria Among Highly Mobile and Hard-to-reach Populations in the Guyanese Shield NCT05540470 | Centre Hospitalier de Cayenne | N/A |
| Completed | Operational Feasibility of Appropriate Plasmodium Vivax Radical Cure After G6PD Testing in Thailand NCT05753150 | Dr. Prayuth Sudathip | — |
| Unknown | Plasmodium Vivax Among Duffy Negative Population in Cameroon. NCT05058885 | University of Dschang | — |
| Terminated | Safety and Immunogenicity of Pvs25-IMX313/Matrix-M1 Vaccine NCT05270265 | University of Oxford | EARLY_Phase 1 |
| Unknown | Serological Screen and Treat Trial for Plasmodium Vivax NCT04223674 | Indonesia University | N/A |
| Completed | Short Course Radical Cure of P. Vivax Malaria in Nepal NCT04079621 | Menzies School of Health Research | Phase 4 |
| Unknown | Operational Feasibility of Appropriate Radical Cure of Plasmodium Vivax With Tafenoquine or Primaquine After Q NCT05096702 | Fundação de Medicina Tropical Dr. Heitor Vieira Dourado | — |
| Completed | Study to Evaluate Primaquine for Radical Cure of Uncomplicated Plasmodium Vivax Malaria in Children NCT05044637 | Fundação de Medicina Tropical Dr. Heitor Vieira Dourado | Phase 2 |
| Unknown | Efficacy of a Synthetic Vaccine Derived From Plasmodium Vivax Circumsporozoite Protein (PvCS) in naïve and Sem NCT04739917 | Malaria Vaccine and Drug Development Center | Phase 2 |
| Completed | Effectiveness of Novel Approaches to Radical Cure With Tafenoquine and Primaquine NCT04411836 | Menzies School of Health Research | Phase 3 |
| Completed | Efficacy of SJ733 in Adults With Uncomplicated Plasmodium Falciparum or Vivax Malaria NCT04709692 | R. Kiplin Guy | Phase 2 |
| Completed | Safety, Immunogenicity and Efficacy of the Blood-stage Plasmodium Vivax Malaria Vaccine Candidate PvDBPII in M NCT04201431 | University of Oxford | Phase 1 / Phase 2 |
| Completed | VAC071: A Study to Assess Efficacy of the ChAd63/MVA PvDBP Vaccines NCT04009096 | University of Oxford | Phase 2 |
| Completed | Combination Momordica Charantia Extract and Primaquine Againts Plasmodium Falciparum Uncomplicated and Plasmod NCT06036030 | Syamsudin Abdillah,Ph.D, Pharm D | Phase 2 |
| Completed | VAC069: A Study of Blood-stage Controlled Human P. Vivax Infection NCT03797989 | University of Oxford | EARLY_Phase 1 |
| Completed | DHA-PQP vs Chloroquine and Primaquine for Radical Cure of Vivax Malaria in Brazil NCT03208907 | Fundação de Medicina Tropical Dr. Heitor Vieira Dourado | Phase 3 |
| Terminated | Assessing a Risk Model for G6PD Deficiency NCT03337152 | PATH | Phase 4 |
| Completed | Efficacy of 3 Regimens of Chloroquine and Primaquine for Treatment of P. Vivax Malaria, Cruzeiro do Sul, Acre, NCT03610399 | Centers for Disease Control and Prevention | N/A |
| Completed | Efficacy and Safety Study of Tafenoquine (TQ) Co-administered With Dihydroartemisinin-piperaquine (DHA-PQP) fo NCT02802501 | GlaxoSmithKline | Phase 3 |
| Completed | Study of Controlled Human Plasmodium Vivax Infection NCT03377296 | University of Oxford | N/A |
| Completed | A Retrospective Study of Severe Plasmodium Vivax NCT03307369 | University of Oxford | — |
| Completed | A Pharmacokinetics, Safety and Efficacy Study of Tafenoquine (TQ) in Pediatric Subjects With Plasmodium Vivax NCT02563496 | GlaxoSmithKline | Phase 2 |
| Completed | A Study to Assess the Effects of Dissolution Profile on the Pharmacokinetics of Single Oral Doses of Tafenoqui NCT02751294 | GlaxoSmithKline | Phase 1 |
| Completed | Assessment of Any Potential Retinal Effects of Tafenoquine (TQ) NCT02658435 | GlaxoSmithKline | Phase 1 |
| Completed | Study to Assess the Incidence of Hemolysis, Safety, and Efficacy of Tafenoquine (SB-252263, WR238605) Versus P NCT02216123 | GlaxoSmithKline | Phase 3 |
| Completed | Efficacy of Chloroquine (CQ) Alone Compared to Concomitant CQ and Primaquine for Plasmodium Vivax Infection NCT02691910 | Oswaldo Cruz Foundation | Phase 2 / Phase 3 |
| Completed | A Study to Evaluate the Pharmacokinetics of a Single Dose of Tafenoquine Co-administered With Either Artemethe NCT02184637 | GlaxoSmithKline | Phase 1 |
| Terminated | Eurartesim® in Patients With Imported Uncomplicated Plasmodium Vivax Malaria NCT02110784 | Alfasigma S.p.A. | Phase 2 |
| Completed | Ph 2B/3 Tafenoquine (TFQ) Study in Prevention of Vivax Relapse NCT01376167 | GlaxoSmithKline | Phase 2 |
| Completed | Tafenoquine Thorough QTc Study in Healthy Subjects NCT01928914 | GlaxoSmithKline | Phase 1 |
| Completed | Efficacy, Tolerability, PK of OZ439 in Adults With Acute, Uncomplicated P.Falciparum or Vivax Malaria Mono-inf NCT01213966 | Medicines for Malaria Venture | Phase 2 |
| Completed | A Study to Investigate the Safety, Tolerability and Pharmacokinetics of OZ439 in Healthy Male and Female Subje NCT00928083 | Medicines for Malaria Venture | Phase 1 |
| Completed | Pilot Human Study of Tinidazole Efficacy For Radical Cure Of Plasmodium Vivax NCT00811096 | Walter Reed Army Institute of Research (WRAIR) | Phase 2 |
| Completed | Safety and Immunogenicity Study of Plasmodium Vivax CS Derived Synthetic Peptides Formulated in Two Adjuvants NCT01081847 | Malaria Vaccine and Drug Development Center | Phase 1 |
| Completed | A Randomised Trial of Artekin and Artesunate & Amodiaquine for Uncomplicated Malaria in Timika, Papua, Indones NCT00157885 | Menzies School of Health Research | N/A |
| Completed | Establishment of a Sporozoite Challenge Model for Plasmodium Vivax in Human Volunteers NCT01083095 | Malaria Vaccine and Drug Development Center | EARLY_Phase 1 |
| Completed | Artesunate Plus Sulfadoxine-Pyrimethamine Versus Chloroquine for Vivax Malaria NCT00486694 | London School of Hygiene and Tropical Medicine | Phase 2 |
| Completed | Therapeutic Efficacy Study of Pyrimethamine/Sulfdoxine (Fansidar®) for the Treatment of Uncomplicated Falcipar NCT00951106 | Walter Reed Army Institute of Research (WRAIR) | N/A |